サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1472159

糖尿病性神経障害治療の世界市場：市場規模・予測 - 疾患タイプ別、薬剤クラス別、流通チャネル別、地域別分析、2023～2030年

Global Diabetic Neuropathy Treatment Market Size study & Forecast, by Disorder Type by Drug Class (Capsaicin, Opioid, Non-Steroidal Anti-inflammatory Drugs, Antidepressants, Others), by Distribution Channel and Regional Analysis, 2023-2030

出版日
ページ情報
英文 200 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
糖尿病性神経障害治療の世界市場：市場規模・予測 - 疾患タイプ別、薬剤クラス別、流通チャネル別、地域別分析、2023～2030年
出版日: 2024年04月20日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文 200 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の糖尿病性神経障害治療の市場規模は、2022年に約40億3,000万米ドルに達し、2023～2030年の予測期間にかけて7.72%以上の健全な成長率で推移すると予測されています。

糖尿病性神経障害治療には、糖尿病による神経障害に伴う症状や合併症の管理を目的としたさまざまな戦略が含まれます。これらの治療法は、痛みの緩和、神経機能の改善、さらなる損傷の予防に重点を置いています。糖尿病性神経障害治療の一般的なアプローチには、薬物療法、生活習慣の改善、代替療法などがあります。糖尿病性神経障害治療市場は、糖尿病有病率の上昇、老人人口の増加、世界のヘルスケア支出の増加などの要因により拡大しています。

世界の糖尿病有病率の上昇は、糖尿病性神経障害治療市場の重要な促進要因です。糖尿病患者数が増加し続けるにつれ、糖尿病性神経障害の発生率も増加し、治療を必要とする患者数が増加しています。国際糖尿病連合のデータによると、2022年には20～79歳の成人の約5億3,700万人が糖尿病に罹患し、世界全体では10人に1人が罹患していることになります。2030年には6億4,300万人に増加し、2045年には7億8,300万人に増加すると予測されています。加えて、新薬や治療法を発見するための研究開発活動が活発化し、患者中心の医療への関心が高まっていることも、市場開拓に新たな機会をもたらしています。しかし、認知度や教育の不足、薬の副作用などが、2023～2030年の予測期間を通じて市場の成長を阻害しています。

糖尿病性神経障害治療の世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、洗練されたヘルスケアインフラと多額の医療費により、糖尿病性神経障害の先進的な治療法を取り入れる環境が整っているため、2022年の市場を独占しました。Abbott社、Pfizer Inc.社、Eli Lilly社、Johnson & Johnson社などの産業大手企業は、この地域に事業基盤を確立しており、市場の拡大をさらに促進しています。さらに、Neuralace Medical社の疼痛性糖尿病性神経障害（PDN）ラベル拡大研究が間もなく完了し、その非侵襲的治療のFDA認可の可能性と相まって、北米の糖尿病性神経障害市場の展望に革命を起こす態勢が整っています。欧州は、ヘルスケアインフラの強化や研究イニシアチブの支援に向けた政府資金の増加による積極的な強化などの要因により、予測期間中に最も速い速度で成長すると予想されます。特に、中央欧州糖尿病協会（CEDA）のような非営利団体は、革新的な製品の開発を推進するために製薬会社との協力的な取り組みを行っており、市場の成長にさらに貢献しています。

本調査の目的は、近年における様々なセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 世界の糖尿病性神経障害治療市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 世界の糖尿病性神経障害治療の市場力学

  • 糖尿病性神経障害治療市場の影響分析（2020～2030年）
    • 市場促進要因
      • 糖尿病有病率の上昇
      • 高齢者人口の増加
      • 世界のヘルスケア支出の増加
    • 市場の課題
      • 認識と教育の欠如
      • 薬の副作用
    • 市場機会
      • 新薬・治療法発見のための研究開発活動の活発化
      • 患者中心の治療への注目の高まり

第4章 世界の糖尿病性神経障害治療市場の産業分析

  • ポーターのファイブフォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターのファイブフォース影響分析
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 産業専門家の視点
  • アナリストの結論・提言

第5章 糖尿病性神経障害治療の世界市場：疾患タイプ別

  • 市場スナップショット
  • 糖尿病性神経障害治療の世界市場：疾患タイプ別、実績 - ポテンシャル分析
  • 糖尿病性神経障害治療の世界市場：疾患タイプ別、推定・予測、2020～2030年
  • 糖尿病性神経障害治療市場、サブセグメント分析
    • 末梢神経障害
    • 自律神経障害
    • 近位神経障害
    • 局所神経障害

第6章 糖尿病性神経障害治療の世界市場：薬剤クラス別

  • 市場スナップショット
  • 糖尿病性神経障害治療の世界市場：薬剤クラス別、実績 - ポテンシャル分析
  • 糖尿病性神経障害治療の世界市場：薬剤クラス別、推定・予測、2020～2030年
  • 糖尿病性神経障害治療市場、サブセグメント分析
    • カプサイシン
    • オピオイド
    • 非ステロイド性抗炎症薬（NSAIDs）
    • 抗うつ薬
    • その他

第7章 糖尿病性神経障害治療の世界市場：流通チャネル別

  • 市場スナップショット
  • 糖尿病性神経障害治療の世界市場：流通チャネル別、実績 - ポテンシャル分析
  • 糖尿病性神経障害治療の世界市場：流通チャネル別、推定・予測、2020～2030年
  • 糖尿病性神経障害治療市場、サブセグメント分析
    • 病院薬局
    • 小売薬局
    • その他

第8章 糖尿病性神経障害治療の世界市場：地域別分析

  • 主要国
  • 主な新興国
  • 糖尿病性神経障害治療市場、地域別市場スナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他の欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他のアジア太平洋
  • ラテンアメリカ
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他の中東・アフリカ

第9章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • Pfizer Inc.
    • Eli Lilly and Company
    • Johnson & Johnson
    • Abbott Laboratories
    • Novo Nordisk A/S
    • Astellas Pharma Inc.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Boehringer Ingelheim International GmbH

第10章 調査プロセス

図表

LIST OF TABLES

  • TABLE 1.Global Diabetic Neuropathy Treatment Market, report scope
  • TABLE 2.Global Diabetic Neuropathy Treatment Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3.Global Diabetic Neuropathy Treatment Market estimates & forecasts by Disorder Type 2020-2030 (USD Billion)
  • TABLE 4.Global Diabetic Neuropathy Treatment Market estimates & forecasts by Drug Class 2020-2030 (USD Billion)
  • TABLE 5.Global Diabetic Neuropathy Treatment Market estimates & forecasts by Distribution Channel 2020-2030 (USD Billion)
  • TABLE 6.Global Diabetic Neuropathy Treatment Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7.Global Diabetic Neuropathy Treatment Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8.Global Diabetic Neuropathy Treatment Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9.Global Diabetic Neuropathy Treatment Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10.Global Diabetic Neuropathy Treatment Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11.Global Diabetic Neuropathy Treatment Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12.Global Diabetic Neuropathy Treatment Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13.Global Diabetic Neuropathy Treatment Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14.Global Diabetic Neuropathy Treatment Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15.Global Diabetic Neuropathy Treatment Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16.U.S. Diabetic Neuropathy Treatment Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17.U.S. Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 18.U.S. Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19.Canada Diabetic Neuropathy Treatment Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 20.Canada Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21.Canada Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22.UK Diabetic Neuropathy Treatment Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 23.UK Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24.UK Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25.Germany Diabetic Neuropathy Treatment Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 26.Germany Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27.Germany Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28.France Diabetic Neuropathy Treatment Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 29.France Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30.France Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31.Italy Diabetic Neuropathy Treatment Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 32.Italy Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33.Italy Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34.Spain Diabetic Neuropathy Treatment Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 35.Spain Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36.Spain Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37.RoE Diabetic Neuropathy Treatment Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 38.RoE Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39.RoE Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40.China Diabetic Neuropathy Treatment Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 41.China Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42.China Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43.India Diabetic Neuropathy Treatment Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 44.India Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45.India Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46.Japan Diabetic Neuropathy Treatment Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 47.Japan Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48.Japan Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49.South Korea Diabetic Neuropathy Treatment Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 50.South Korea Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51.South Korea Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52.Australia Diabetic Neuropathy Treatment Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 53.Australia Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54.Australia Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55.RoAPAC Diabetic Neuropathy Treatment Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 56.RoAPAC Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57.RoAPAC Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58.Brazil Diabetic Neuropathy Treatment Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 59.Brazil Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60.Brazil Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61.Mexico Diabetic Neuropathy Treatment Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 62.Mexico Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63.Mexico Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64.RoLA Diabetic Neuropathy Treatment Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 65.RoLA Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66.RoLA Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67.Saudi Arabia Diabetic Neuropathy Treatment Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 68.South Africa Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69.RoMEA Diabetic Neuropathy Treatment Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70.List of secondary sources, used in the study of global Diabetic Neuropathy Treatment Market
  • TABLE 71.List of primary sources, used in the study of global Diabetic Neuropathy Treatment Market
  • TABLE 72.Years considered for the study
  • TABLE 73.Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1.Global Diabetic Neuropathy Treatment Market, research methodology
  • FIG 2.Global Diabetic Neuropathy Treatment Market, Market estimation techniques
  • FIG 3.Global Market size estimates & forecast methods
  • FIG 4.Global Diabetic Neuropathy Treatment Market, key trends 2022
  • FIG 5.Global Diabetic Neuropathy Treatment Market, growth prospects 2023-2030
  • FIG 6.Global Diabetic Neuropathy Treatment Market, porters 5 force model
  • FIG 7.Global Diabetic Neuropathy Treatment Market, pest analysis
  • FIG 8.Global Diabetic Neuropathy Treatment Market, value chain analysis
  • FIG 9.Global Diabetic Neuropathy Treatment Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10.Global Diabetic Neuropathy Treatment Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11.Global Diabetic Neuropathy Treatment Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12.Global Diabetic Neuropathy Treatment Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13.Global Diabetic Neuropathy Treatment Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14.Global Diabetic Neuropathy Treatment Market, regional snapshot 2020 & 2030
  • FIG 15.North America Diabetic Neuropathy Treatment Market 2020 & 2030 (USD Billion)
  • FIG 16.Europe Diabetic Neuropathy Treatment Market 2020 & 2030 (USD Billion)
  • FIG 17.Asia pacific Diabetic Neuropathy Treatment Market 2020 & 2030 (USD Billion)
  • FIG 18.Latin America Diabetic Neuropathy Treatment Market 2020 & 2030 (USD Billion)
  • FIG 19.Middle East & Africa Diabetic Neuropathy Treatment Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Diabetic Neuropathy Treatment Market is valued approximately USD 4.03 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 7.72% over the forecast period 2023-2030. Diabetic neuropathy treatment encompasses a range of strategies aimed at managing the symptoms and complications associated with nerve damage caused by diabetes. These treatments focus on alleviating pain, improving nerve function, and preventing further damage. Common approaches to diabetic neuropathy treatment include medication therapy, lifestyle modifications, and alternative therapies. The Diabetic Neuropathy Treatment market is expanding because of factors such as rising prevalence of diabetes, rising geriatric population and increasing healthcare expenditure across worldwide.

The rising prevalence of diabetes worldwide is a significant driver of the diabetic neuropathy treatment market. As the number of individuals with diabetes continues to grow, so does the incidence of diabetic neuropathy, creating a larger patient pool in need of treatment. As per data from the International Diabetes Federation, the year 2022 witnessed approximately 537 million adults aged 20 to 79 affected by diabetes, translating to 1 in 10 individuals globally. Projections indicate a steady increase, with an estimated rise to 643 million by 2030 and further escalation to 783 million by 2045. In addition, rising research and development activities to discover new drugs and therapies and growing focus on patient-centric care are creating new opportunities to the market growth. However, lack of awareness and education and side effects of medications stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Diabetic Neuropathy Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the the region's sophisticated healthcare infrastructure and substantial healthcare expenditure, fostering an environment conducive to the uptake of advanced treatments for diabetic neuropathy. Leading industry players such as Abbott, Pfizer Inc., Eli Lilly, and Johnson & Johnson have established operational footholds in this region, further fueling market expansion. Additionally, the imminent completion of Neuralace Medical's Painful Diabetic Neuropathy (PDN) label expansion study, coupled with the potential FDA clearance for its non-invasive treatment, stands poised to revolutionize the diabetic neuropathy market landscape in North America. Europe is expected to grow at a fastest rate during the forecast period, owing to factors such as positive reinforcement due to escalating government funding directed towards enhancing healthcare infrastructure and supporting research initiatives. Notably, nonprofit organizations like the Central European Diabetes Association (CEDA) engage in collaborative efforts with pharmaceutical companies to drive the development of innovative products, further contributing to market growth.

Major market player included in this report are:

  • Pfizer Inc.
  • Eli Lilly and Company
  • Johnson & Johnson
  • Abbott Laboratories
  • Novo Nordisk A/S
  • Astellas Pharma Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH

Recent Developments in the Market:

  • In December 2023, Vertex Pharmaceuticals achieved FDA approval for its CRISPR-based gene editing therapy, marking a strategic milestone in its focus on advancing non-opioid pain management drugs. Leveraging the promising results from Vertex's phase 2 clinical trial of VX-548, this emphasis on alternative pain relief methods reflects the growing demand for safer and more efficient treatments for diabetic peripheral neuropathy. By addressing this critical need for innovative solutions, Vertex Pharmaceuticals secures a competitive advantage in the market.
  • In July 2023, Asprius Lifesciences, an Indian pharmaceutical company, unveiled a new treatment for Diabetic Neuropathy, a condition characterized by nerve damage in peripheral body areas. Notably, the company has filed a patent for a Fixed-Dose Combination (FDC), showcasing potential in tackling peripheral neuropathy. This significant development positions Asprius as a formidable contender in the global market, meeting the widespread demand for effective solutions.

Global Diabetic Neuropathy Treatment Market Report Scope:

  • Historical Data - 2020 - 2021
  • Base Year for Estimation - 2022
  • Forecast period - 2023-2030
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered - Disorder Type, Drug Class, Distribution Channel, Region
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Disorder Type:

  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy

By Drug Class:

  • Capsaicin
  • Opioid
  • Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
  • Antidepressants
  • Others

By Distribution Channel:

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Other

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1.Executive Summary

  • 1.1.Market Snapshot
  • 1.2.Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1.Diabetic Neuropathy Treatment Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2.Diabetic Neuropathy Treatment Market, by Disorder Type, 2020-2030 (USD Billion)
    • 1.2.3.Diabetic Neuropathy Treatment Market, by Drug Class, 2020-2030 (USD Billion)
    • 1.2.4.Diabetic Neuropathy Treatment Market, by Distribution Channel, 2020-2030 (USD Billion)
  • 1.3.Key Trends
  • 1.4.Estimation Methodology
  • 1.5.Research Assumption

Chapter 2.Global Diabetic Neuropathy Treatment Market Definition and Scope

  • 2.1.Objective of the Study
  • 2.2.Market Definition & Scope
    • 2.2.1.Industry Evolution
    • 2.2.2.Scope of the Study
  • 2.3.Years Considered for the Study
  • 2.4.Currency Conversion Rates

Chapter 3.Global Diabetic Neuropathy Treatment Market Dynamics

  • 3.1.Diabetic Neuropathy Treatment Market Impact Analysis (2020-2030)
    • 3.1.1.Market Drivers
      • 3.1.1.1.Rising prevalence of diabetes
      • 3.1.1.2.Rising geriatric population
      • 3.1.1.3. Increasing healthcare expenditure across worldwide
    • 3.1.2.Market Challenges
      • 3.1.2.1.Lack of awareness and education
      • 3.1.2.2.Side effects of medications
    • 3.1.3.Market Opportunities
      • 3.1.3.1.Rising research and development activities to discover new drugs and therapies
      • 3.1.3.2.Growing focus on patient-centric care

Chapter 4.Global Diabetic Neuropathy Treatment Market Industry Analysis

  • 4.1.Porter's 5 Force Model
    • 4.1.1.Bargaining Power of Suppliers
    • 4.1.2.Bargaining Power of Buyers
    • 4.1.3.Threat of New Entrants
    • 4.1.4.Threat of Substitutes
    • 4.1.5.Competitive Rivalry
  • 4.2.Porter's 5 Force Impact Analysis
  • 4.3.PEST Analysis
    • 4.3.1.Political
    • 4.3.2.Economical
    • 4.3.3.Social
    • 4.3.4.Technological
    • 4.3.5.Environmental
    • 4.3.6.Legal
  • 4.4.Top investment opportunity
  • 4.5.Top winning strategies
  • 4.6.COVID-19 Impact Analysis
  • 4.7.Disruptive Trends
  • 4.8.Industry Expert Perspective
  • 4.9.Analyst Recommendation & Conclusion

Chapter 5.Global Diabetic Neuropathy Treatment Market, by Disorder Type

  • 5.1.Market Snapshot
  • 5.2.Global Diabetic Neuropathy Treatment Market by Disorder Type, Performance - Potential Analysis
  • 5.3.Global Diabetic Neuropathy Treatment Market Estimates & Forecasts by Disorder Type 2020-2030 (USD Billion)
  • 5.4.Diabetic Neuropathy Treatment Market, Sub Segment Analysis
    • 5.4.1. Peripheral Neuropathy
    • 5.4.2.Autonomic Neuropathy
    • 5.4.3.Proximal Neuropathy
    • 5.4.4.Focal Neuropathy

Chapter 6.Global Diabetic Neuropathy Treatment Market, by Drug Class

  • 6.1.Market Snapshot
  • 6.2.Global Diabetic Neuropathy Treatment Market by Drug Class, Performance - Potential Analysis
  • 6.3.Global Diabetic Neuropathy Treatment Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
  • 6.4.Diabetic Neuropathy Treatment Market, Sub Segment Analysis
    • 6.4.1. Capsaicin
    • 6.4.2.Opioid
    • 6.4.3.Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
    • 6.4.4.Antidepressants
    • 6.4.5.Others

Chapter 7.Global Diabetic Neuropathy Treatment Market, by Distribution Channel

  • 7.1.Market Snapshot
  • 7.2.Global Diabetic Neuropathy Treatment Market by Distribution Channel, Performance - Potential Analysis
  • 7.3.Global Diabetic Neuropathy Treatment Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
  • 7.4.Diabetic Neuropathy Treatment Market, Sub Segment Analysis
    • 7.4.1. Hospitals Pharmacies
    • 7.4.2.Retail Pharmacies
    • 7.4.3.Other

Chapter 8.Global Diabetic Neuropathy Treatment Market, Regional Analysis

  • 8.1.Top Leading Countries
  • 8.2.Top Emerging Countries
  • 8.3.Diabetic Neuropathy Treatment Market, Regional Market Snapshot
  • 8.4.North America Diabetic Neuropathy Treatment Market
    • 8.4.1.U.S. Diabetic Neuropathy Treatment Market
      • 8.4.1.1.Disorder Type breakdown estimates & forecasts, 2020-2030
      • 8.4.1.2.Drug Class breakdown estimates & forecasts, 2020-2030
      • 8.4.1.3.Distribution Channel breakdown estimates & forecasts, 2020-2030
    • 8.4.2.Canada Diabetic Neuropathy Treatment Market
  • 8.5.Europe Diabetic Neuropathy Treatment Market Snapshot
    • 8.5.1.U.K. Diabetic Neuropathy Treatment Market
    • 8.5.2.Germany Diabetic Neuropathy Treatment Market
    • 8.5.3.France Diabetic Neuropathy Treatment Market
    • 8.5.4.Spain Diabetic Neuropathy Treatment Market
    • 8.5.5.Italy Diabetic Neuropathy Treatment Market
    • 8.5.6.Rest of Europe Diabetic Neuropathy Treatment Market
  • 8.6.Asia-Pacific Diabetic Neuropathy Treatment Market Snapshot
    • 8.6.1.China Diabetic Neuropathy Treatment Market
    • 8.6.2.India Diabetic Neuropathy Treatment Market
    • 8.6.3.Japan Diabetic Neuropathy Treatment Market
    • 8.6.4.Australia Diabetic Neuropathy Treatment Market
    • 8.6.5.South Korea Diabetic Neuropathy Treatment Market
    • 8.6.6.Rest of Asia Pacific Diabetic Neuropathy Treatment Market
  • 8.7.Latin America Diabetic Neuropathy Treatment Market Snapshot
    • 8.7.1.Brazil Diabetic Neuropathy Treatment Market
    • 8.7.2.Mexico Diabetic Neuropathy Treatment Market
  • 8.8.Middle East & Africa Diabetic Neuropathy Treatment Market
    • 8.8.1.Saudi Arabia Diabetic Neuropathy Treatment Market
    • 8.8.2.South Africa Diabetic Neuropathy Treatment Market
    • 8.8.3.Rest of Middle East & Africa Diabetic Neuropathy Treatment Market

Chapter 9.Competitive Intelligence

  • 9.1.Key Company SWOT Analysis
  • 9.2.Top Market Strategies
  • 9.3.Company Profiles
    • 9.3.1. Pfizer Inc.
      • 9.3.1.1.Key Information
      • 9.3.1.2.Overview
      • 9.3.1.3.Financial (Subject to Data Availability)
      • 9.3.1.4.Product Summary
      • 9.3.1.5.Recent Developments
    • 9.3.2. Eli Lilly and Company
    • 9.3.3.Johnson & Johnson
    • 9.3.4.Abbott Laboratories
    • 9.3.5.Novo Nordisk A/S
    • 9.3.6.Astellas Pharma Inc.
    • 9.3.7.GlaxoSmithKline plc
    • 9.3.8.Merck & Co., Inc.
    • 9.3.9.Teva Pharmaceutical Industries Ltd.
    • 9.3.10.Boehringer Ingelheim International GmbH

Chapter 10.Research Process

  • 10.1.Research Process
    • 10.1.1.Data Mining
    • 10.1.2.Analysis
    • 10.1.3.Market Estimation
    • 10.1.4.Validation
    • 10.1.5.Publishing
  • 10.2.Research Attributes
  • 10.3.Research Assumption